CDC Website CDC Website

To Join the NPIN community or

You are here

Federal Government Agencies

Long-Term Retention in Care for U.S. Substance Using Populations (R21)

NPIN admin's picture
Grant Amount: Unspecified. Until there is a cure, people living with HIV (PLWH) will have to be retained in care throughout their lives. Therefore, the purpose of this Funding Opportunity Announcement (FOA) is to encourage research on long-term retention in care leading to sustained viral suppression among substance abusers. This FOA offers the opportunity to conduct exploratory research focused on long-term retention in care.

Long-Term Retention in Care for U.S. Substance Using Populations (R34)

NPIN admin's picture
Grant Amount: Unspecified. Until there is a cure, people living with HIV (PLWH) will have to be retained in care throughout their lives. Therefore, the purpose of this Funding Opportunity Announcement (FOA) is to encourage research on long-term retention in care leading to sustained viral suppression among substance abusers. This FOA (R34) offers the opportunity to conduct the initial development of a clinical trial or research project focused on long-term retention in care for substance users.

Long-Term Retention in Care for U.S. Substance Using Populations (R01)

NPIN admin's picture
Grant Amount: Unspecified. Until there is a cure, people living with HIV (PLWH) will have to be retained in care throughout their lives. Therefore, the purpose of this Funding Opportunity Announcement (FOA) is to encourage research on long-term retention in care leading to sustained viral suppression among substance abusers.

Fc Receptor (FcR) and Antibody Effector Function in HIV Vaccine Discovery (R01)

NPIN admin's picture
Grant Amount: Unspecified. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate and support investigator-driven collaborative research to: (1) probe how vaccine elicited antibodies protect against viral acquisition via Fc receptor (FcR) mediated mechanisms; and (2) benchmark functional profiles of vaccines that protect against viral infections to inform advancement of HIV vaccine candidates.

B Cell Help Immunology Program for AIDS Vaccine Strategies (R01)

NPIN admin's picture
Grant Amount: Unspecified. The purpose of this Funding Opportunity Announcement (FOA) is to: (1) support multidisciplinary projects that define the role(s) played by innate immunity and T cells in shaping the B cell response to HIV-1 antigens; and (2) identify strategies to modulate innate immune mechanisms and T cell differentiation pathways to optimize B cell helper functions for enhancing HIV-1 vaccines and generating long-term memory.

HIV Vaccine Vector-Host Interactions: Understanding the Biology and Immunology (R01)

NPIN admin's picture
Grant Amount: Unspecified. The purpose of this Funding Opportunity Announcement (FOA) is to develop an increased understanding of the biology and immunology of natural viral infections and HIV vaccine vectors derived from these viruses. Applications should focus on four types of vaccine viral vector platforms developed from Adenoviridae, Poxviridae, Herpesviridae, and Adeno-associated viruses in humans or non-human primates (NHPs).

HIV Vaccine Vector-Host Interactions: Understanding the Biology and Immunology (R21)

NPIN admin's picture
Grant Amount: Unspecified. The purpose of this Funding Opportunity Announcement (FOA) is to develop an increased understanding of the biology and immunology of natural viral infections and HIV vaccine vectors derived from these viruses. Applications should focus on four types of vaccine viral vector platforms developed from Adenoviridae, Poxviridae, Herpesviridae, and Adeno-associated viruses in humans or non-human primates (NHPs).

Clinical Trial Planning Grant for Interventions and Services to Improve Treatment and Prevention of HIV/AIDS (R34)

NPIN admin's picture
Grant Amount: Unspecified. This Funding Opportunity Announcement (FOA) invites Clinical Trial Planning Grant applications that propose planning, design, and preparation of documentation necessary for implementation of investigator-initiated clinical trials related to HIV treatment and prevention. This includes evaluating the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention or treatment, and includes populations with co-infections and comorbidities.

Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2)

NPIN admin's picture
Grant Amount: NIDA intends to commit $1.5M in each fiscal year (FY 2015-2017) to fund 2-3 awards. Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies at the nexus of substance abuse and HIV/AIDS. This award is designed to support creative individuals who wish to pursue innovative research approaches for substance using populations with or at risk for HIV/AIDS.

Pages

Subscribe to RSS - Federal Government Agencies